OnCo
technologiesTechnologyEstablished

CRISPR functional genomics

Knocking out every gene one at a time in cancer cells to find which ones they cannot live without.

Genome-wide knockout, activation, and base-editing screens across >1,000 cell lines (DepMap, Sanger Project Score) map cancer dependencies and synthetic-lethal pairs (PRMT5/MTAP, WRN/MSI). In vivo and immune co-culture screens find immunotherapy resistance genes.

Schematic · not to scale
Guide RNA library · Knockout → dependency

How it works

Pooled sgRNA libraries; depletion or enrichment measured by sequencing.

Strengths
  • Systematic, unbiased dependency maps
Limitations
  • Cell line artefacts; context specificity

Key papers

1top

Latest papers

top
Literature trend422 papers in the last 12 months+22% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"CRISPR screen" OR ABSTRACT:"CRISPR screen" OR TITLE:"genome-wide CRISPR" OR ABSTRACT:"genome-wide CRISPR" OR TITLE:"CRISPR-Cas9 screen" OR ABSTRACT:"CRISPR-Cas9 screen") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CRISPR functional genomics, not a curated reading list.

Connected

62top

Pages like this

not linked directly; found by shared links

fronts

1

technologies

8

targets

1

companies

1

institutions

10

pathways

2

terms

3

roadmaps

1

ideas

23
A drug screen that only rewards killing sleeping cancer cellsA pre-competitive consortium to validate or kill academic targets before licensingA synthetic lethality map for every cancer driver in every tissue contextA virtual cancer cell that predicts what a drug will do before you test itAn open atlas of collateral sensitivity for every approved targeted drugAn open engine that ranks every drug pair by predicted synergy before anyone runs a trialAn open foundation model of the cancer cell trained on perturbation dataAn open model of every cancer cell state, built from perturbation atlasesAttack the backup copy when a tumour has lost the original geneBarcode patient-derived tumours to watch which clones win under each drugDegraders for the fusion proteins that drive childhood sarcomasEvery drug screen includes standard reference compounds whose performance is publishedEvery resistance mechanism found in a patient must be rebuilt in the laboratoryGroup trials by broken mechanism, not by organ or single mutationMake bespoke mouse cancer models in weeks with in vivo gene editingMake in vivo metastasis screens a required step in drug discoveryPRMT5/MAT2A synthetic lethality for MTAP-deleted mesotheliomaSelf-driving laboratories that run the cancer biology hypothesis loop autonomouslySet aside 3% of grant budgets to replicate findings before translationSwitch off an undruggable oncogene permanently with epigenetic editingTest every possible mutation in every cancer gene so no result is 'uncertain'Turn chromosomal chaos into a weakness with KIF18A inhibitorsWRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers

collections

1

people

6

bottlenecks

4

key papers

1